Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
Go back to Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19| (NYSE: OGN) | Delayed: 13.45 +0.05 (0.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.40 | 52 Week High | $8.00 | |||
| Open | $13.40 | 52 Week Low | $8.00 | |||
| Day High | $13.46 | P/E | N/A | |||
| Day Low | $13.39 | EPS | $0.00 | |||
| Volume | 1,533,729 | |||||
